378 related articles for article (PubMed ID: 26062626)
1. Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium.
Marder K; Wang Y; Alcalay RN; Mejia-Santana H; Tang MX; Lee A; Raymond D; Mirelman A; Saunders-Pullman R; Clark L; Ozelius L; Orr-Urtreger A; Giladi N; Bressman S;
Neurology; 2015 Jul; 85(1):89-95. PubMed ID: 26062626
[TBL] [Abstract][Full Text] [Related]
2. Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry.
Lee AJ; Wang Y; Alcalay RN; Mejia-Santana H; Saunders-Pullman R; Bressman S; Corvol JC; Brice A; Lesage S; Mangone G; Tolosa E; Pont-Sunyer C; Vilas D; Schüle B; Kausar F; Foroud T; Berg D; Brockmann K; Goldwurm S; Siri C; Asselta R; Ruiz-Martinez J; Mondragón E; Marras C; Ghate T; Giladi N; Mirelman A; Marder K;
Mov Disord; 2017 Oct; 32(10):1432-1438. PubMed ID: 28639421
[TBL] [Abstract][Full Text] [Related]
3. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?
Orr-Urtreger A; Shifrin C; Rozovski U; Rosner S; Bercovich D; Gurevich T; Yagev-More H; Bar-Shira A; Giladi N
Neurology; 2007 Oct; 69(16):1595-602. PubMed ID: 17938369
[TBL] [Abstract][Full Text] [Related]
4. Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease.
Alcalay RN; Mejia-Santana H; Mirelman A; Saunders-Pullman R; Raymond D; Palmese C; Caccappolo E; Ozelius L; Orr-Urtreger A; Clark L; Giladi N; Bressman S; Marder K;
Parkinsonism Relat Disord; 2015 Feb; 21(2):106-10. PubMed ID: 25434972
[TBL] [Abstract][Full Text] [Related]
5. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease.
Clark LN; Wang Y; Karlins E; Saito L; Mejia-Santana H; Harris J; Louis ED; Cote LJ; Andrews H; Fahn S; Waters C; Ford B; Frucht S; Ottman R; Marder K
Neurology; 2006 Nov; 67(10):1786-91. PubMed ID: 17050822
[TBL] [Abstract][Full Text] [Related]
6. Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.
Alcalay RN; Mirelman A; Saunders-Pullman R; Tang MX; Mejia Santana H; Raymond D; Roos E; Orbe-Reilly M; Gurevich T; Bar Shira A; Gana Weisz M; Yasinovsky K; Zalis M; Thaler A; Deik A; Barrett MJ; Cabassa J; Groves M; Hunt AL; Lubarr N; San Luciano M; Miravite J; Palmese C; Sachdev R; Sarva H; Severt L; Shanker V; Swan MC; Soto-Valencia J; Johannes B; Ortega R; Fahn S; Cote L; Waters C; Mazzoni P; Ford B; Louis E; Levy O; Rosado L; Ruiz D; Dorovski T; Pauciulo M; Nichols W; Orr-Urtreger A; Ozelius L; Clark L; Giladi N; Bressman S; Marder KS
Mov Disord; 2013 Dec; 28(14):1966-71. PubMed ID: 24243757
[TBL] [Abstract][Full Text] [Related]
7. Interest in genetic testing in Ashkenazi Jewish Parkinson's disease patients and their unaffected relatives.
Gupte M; Alcalay RN; Mejia-Santana H; Raymond D; Saunders-Pullman R; Roos E; Orbe-Reily M; Tang MX; Mirelman A; Ozelius L; Orr-Urtreger A; Clark L; Giladi N; Bressman S; Marder K
J Genet Couns; 2015 Apr; 24(2):238-46. PubMed ID: 25127731
[TBL] [Abstract][Full Text] [Related]
8. Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.
Agalliu I; San Luciano M; Mirelman A; Giladi N; Waro B; Aasly J; Inzelberg R; Hassin-Baer S; Friedman E; Ruiz-Martinez J; Marti-Masso JF; Orr-Urtreger A; Bressman S; Saunders-Pullman R
JAMA Neurol; 2015 Jan; 72(1):58-65. PubMed ID: 25401981
[TBL] [Abstract][Full Text] [Related]
9. Age at Onset of Parkinson's Disease Among Ashkenazi Jewish Patients: Contribution of Environmental Factors, LRRK2 p.G2019S and GBA p.N370S Mutations.
Yahalom G; Rigbi A; Israeli-Korn S; Krohn L; Rudakou U; Ruskey JA; Benshimol L; Tsafnat T; Gan-Or Z; Hassin-Baer S; Greenbaum L
J Parkinsons Dis; 2020; 10(3):1123-1132. PubMed ID: 32310186
[TBL] [Abstract][Full Text] [Related]
10. The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers.
Inzelberg R; Cohen OS; Aharon-Peretz J; Schlesinger I; Gershoni-Baruch R; Djaldetti R; Nitsan Z; Ephraty L; Tunkel O; Kozlova E; Inzelberg L; Kaplan N; Fixler Mehr T; Mory A; Dagan E; Schechtman E; Friedman E; Hassin-Baer S
Neurology; 2012 Mar; 78(11):781-6. PubMed ID: 22323743
[TBL] [Abstract][Full Text] [Related]
11. Motor progression of Parkinson's disease with the leucine-rich repeat kinase 2 G2019S mutation.
Yahalom G; Orlev Y; Cohen OS; Kozlova E; Friedman E; Inzelberg R; Hassin-Baer S
Mov Disord; 2014 Jul; 29(8):1057-60. PubMed ID: 24903616
[TBL] [Abstract][Full Text] [Related]
12. The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel.
Hassin-Baer S; Laitman Y; Azizi E; Molchadski I; Galore-Haskel G; Barak F; Cohen OS; Friedman E
J Neurol; 2009 Mar; 256(3):483-7. PubMed ID: 19412725
[TBL] [Abstract][Full Text] [Related]
13. High frequency and reduced penetrance of LRRK2 G2019S mutation among Parkinson's disease patients in Cantabria (Spain).
Sierra M; González-Aramburu I; Sánchez-Juan P; Sánchez-Quintana C; Polo JM; Berciano J; Combarros O; Infante J
Mov Disord; 2011 Nov; 26(13):2343-6. PubMed ID: 21954089
[TBL] [Abstract][Full Text] [Related]
14. Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study.
Mestre TA; Pont-Sunyer C; Kausar F; Visanji NP; Ghate T; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Faust-Socher A; Kasten M; Wadia PM; Zadikoff C; Kumar P; de Bie RM; Thomsen T; Lang AE; Schüle B; Klein C; Tolosa E; Marras C
Mov Disord; 2018 Jul; 33(6):960-965. PubMed ID: 29665080
[TBL] [Abstract][Full Text] [Related]
15. LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease.
Saunders-Pullman R; Barrett MJ; Stanley KM; Luciano MS; Shanker V; Severt L; Hunt A; Raymond D; Ozelius LJ; Bressman SB
Mov Disord; 2010 Nov; 25(15):2536-41. PubMed ID: 20818610
[TBL] [Abstract][Full Text] [Related]
16. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
[TBL] [Abstract][Full Text] [Related]
17. Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations.
Yahalom G; Greenbaum L; Israeli-Korn S; Fay-Karmon T; Livneh V; Ruskey JA; Roncière L; Alam A; Gan-Or Z; Hassin-Baer S
Parkinsonism Relat Disord; 2019 May; 62():179-184. PubMed ID: 30573413
[TBL] [Abstract][Full Text] [Related]
18. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset.
Gan-Or Z; Giladi N; Rozovski U; Shifrin C; Rosner S; Gurevich T; Bar-Shira A; Orr-Urtreger A
Neurology; 2008 Jun; 70(24):2277-83. PubMed ID: 18434642
[TBL] [Abstract][Full Text] [Related]
19. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S
Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868
[TBL] [Abstract][Full Text] [Related]
20. Glucocerebrosidase mutations are not found in association with LRRK2 G2019S in subjects with parkinsonism.
Eblan MJ; Scholz S; Stubblefield B; Gutti U; Goker-Alpan O; Hruska KS; Singleton AB; Sidransky E
Neurosci Lett; 2006 Aug; 404(1-2):163-5. PubMed ID: 16781064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
